Compare CPAY & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPAY | INCY |
|---|---|---|
| Founded | 1986 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.8B | 24.5B |
| IPO Year | 2010 | 1994 |
| Metric | CPAY | INCY |
|---|---|---|
| Price | $453.50 | $118.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 28 |
| Target Price | ★ $496.67 | $132.25 |
| AVG Volume (30 Days) | 441.3K | ★ 1.6M |
| Earning Date | 11-04-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.59 | ★ 4173.33 |
| EPS | ★ 14.44 | 0.50 |
| Revenue | ★ $4,528,403,000.00 | $3,394,635,000.00 |
| Revenue This Year | $18.27 | $17.74 |
| Revenue Next Year | $8.33 | $4.35 |
| P/E Ratio | ★ $31.32 | $238.20 |
| Revenue Growth | ★ 13.93 | 13.67 |
| 52 Week Low | $276.82 | $89.25 |
| 52 Week High | $479.53 | $132.60 |
| Indicator | CPAY | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 63.04 | 50.25 |
| Support Level | $390.93 | $115.38 |
| Resistance Level | $479.53 | $119.29 |
| Average True Range (ATR) | 12.15 | 3.69 |
| MACD | 1.96 | 0.06 |
| Stochastic Oscillator | 66.50 | 45.42 |
Corpay Inc is a corporate payments company that helps businesses and consumers manage and pay their expenses. The company offers payment and spend management solutions, including accounts payable automation, cross-border payments, commercial card programs, vehicle payment solutions, and lodging payment services. Its reportable segments are: Corporate Payments, Vehicle Payments, Lodging Payments and Other. The majority of the company's revenue is derived from the Vehicle Payments segment, which helps customers to pay for vehicle related expenses. Geographically, it derives the maximum revenue from the United States and the rest from Brazil, the United Kingdom and other countries.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.